Table 1.
Patient baseline demographic and clinical characteristics
| Total | First LOT | |||||||
|---|---|---|---|---|---|---|---|---|
| GEM + DOC | DOX | PAZO | DOX + IFO | GEM | Others | Overall p value | ||
| N (%) | 555 (100) | 124 (22.3) | 72 (13.0) | 38 (6.8) | 31 (5.6) | 29 (5.2) | 261 (47.0) | |
| Age, mean (95% CI) | 58.8 (57.5–60.2) | 57.1 (54.9–59.3) | 65.9 (62.5–69.3) | 59.0 (53.3–64.7) | 54.7 (48.9–60.4) | 66.3 (61.5–71.1) | 57.4 (55.2–59.5) | < 0.001 |
| Age categories, n (%) | ||||||||
| 18–44 | 108 (19.5) | 17 (13.7) | 6 (8.3) | 11 (29.0) | 10 (32.3) | 1 (3.5) | 63 (24.1) | < 0.001 |
| 45–54 | 91 (16.4) | 30 (24.2) | 9 (12.5) | 3 (7.9) | 3 (9.7) | 4 (13.8) | 42 (16.1) | 0.091 |
| 55–64 | 132 (23.8) | 42 (33.9) | 16 (22.2) | 8 (21.1) | 7 (22.6) | 6 (20.7) | 53 (20.3) | 0.104 |
| 65–74 | 128 (23.1) | 28 (22.6) | 19 (26.4) | 8 (21.1) | 10 (32.3) | 8 (27.6) | 55 (21.1) | 0.708 |
| 75+ | 96 (17.3) | 7 (5.7) | 22 (30.6) | 8 (21.1) | 1 (3.2) | 10 (34.5) | 48 (18.4) | < 0.001 |
| Female, n (%) | 257 (46.3) | 75 (60.5) | 36 (50.0) | 21 (55.3) | 10 (32.3) | 13 (44.8) | 102 (39.1) | 0.001 |
| Coverage type, n (%) | ||||||||
| Commercial | 363 (65.4) | 90 (72.6) | 38 (52.8) | 28 (73.7) | 22 (71.0) | 15 (51.7) | 170 (65.1) | 0.036 |
| Aged < 65 years | 318 (87.6) | 85 (94.4) | 30 (79.0) | 22 (78.6) | 20 (90.9) | 10 (66.7) | 151 (88.8) | 0.010 |
| Aged 65+ years | 45 (12.4) | 5 (5.6) | 8 (21.1) | 6 (21.4) | 2 (9.1) | 5 (33.3) | 19 (11.1) | 0.010 |
| Medicare advantage | 192 (34.6) | 34 (27.4) | 34 (47.2) | 10 (26.3) | 9 (29.0) | 14 (48.3) | 91 (34.9) | 0.036 |
| Geographic region, n (%) | ||||||||
| Northeast | 92 (16.6) | 17 (13.7) | 11 (15.3) | 7 (18.4) | 8 (25.8) | 6 (20.7) | 43 (16.5) | 0.672 |
| Midwest | 151 (27.2) | 32 (25.8) | 24 (33.3) | 10 (26.3) | 8 (25.8) | 9 (31.0) | 68 (26.1) | 0.860 |
| South | 228 (41.1) | 57 (46.0) | 25 (34.7) | 17 (44.7) | 9 (29.0) | 9 (31.0) | 111 (42.5) | 0.313 |
| West | 84 (15.1) | 18 (14.5) | 12 (16.7) | 4 (10.5) | 6 (19.4) | 5 (17.2) | 39 (14.9) | 0.931 |
| Quan-Charlson comorbidity score, mean (95% CI) | 7.6 (7.4–7.7) | 7.4 (7.1–7.7) | 7.7 (7.4–8.1) | 7.6 (6.9–8.3) | 6.9 (6.5–7.4) | 8.0 (7.3–8.6) | 7.6 (7.4–7.8) | 0.166 |
| ≥ 1 Radiation claim, n (%) | 251 (45.2) | 37 (29.8) | 44 (61.1) | 18 (47.4) | 9 (29.0) | 14 (48.3) | 129 (49.4) | < 0.001 |
| ≥ 1 Surgery claim, n (%) | 397 (71.5) | 96 (77.4) | 53 (73.6) | 28 (73.7) | 20 (64.5) | 20 (69.0) | 180 (69.0) | 0.544 |
| Length of follow-up (days), mean (95% CI) | 325.8 (303.6–347.9) | 363.6 (313.9–413.3) | 316.0 (261.8–370.2) | 317.8 (234.6–401.0) | 365.4 (254.9–475.8) | 186.1 (121.3–251.0) | 322.4 (289.6–355.3) | 0.043 |
DOC docetaxel, DOX doxorubicin, GEM gemcitabine, IFO ifosfamide, PAZO pazopanib, SD standard deviation